Suggested remit: To appraise the clinical and cost effectiveness of tocilizumab within its marketing authorisation for treating systemic sclerosis.
Status Awaiting development
Decision None selected
Process TA
ID number 1396

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
04 July 2018 (14:00) Scoping workshop (Manchester)
28 June 2018 The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of tocilizumab for treating systemic sclerosis ID1396 We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal. The company that market tocilizumab have shared confidential information with NICE, in light of this information NICE will not be progressing with the scoping exercise consequently the scoping workshop arranged for the 4 July 2018 will be cancelled. NICE will monitor this topic and may begin the scoping process again at a more suitable time. We apologise for any inconvenience this may cause. If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar on at
15 May 2018 - 13 June 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual